Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Red Flags for Biogen's Future

TheMotleyFool

0 0

Biotech giant Biogen (NASDAQ: BIIB) has generated many headlines in the past couple of years, largely due to its Alzheimer's disease (AD) therapy, Aduhelm, and that drug's controversial path to approval in the U.S. However, this landmark regulatory win hasn't been enough to save Biogen's performance.

The company's shares have significantly lagged the market in the past year. Unfortunately, it could get worse before it gets better for the biotech. Let's look at two red flags that Biogen is currently facing and discuss whether it is worth it to purchase the company's shares right now.